Relmada Therapeutics (RLMD) Stock Forecast, Price Target & Predictions


OverviewOwnershipFinancialsChartTranscripts

RLMD Stock Forecast


Relmada Therapeutics stock forecast is as follows: an average price target of $5.67 (represents a 66.76% upside from RLMD’s last price of $3.40) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.

RLMD Price Target


The average price target for Relmada Therapeutics (RLMD) is $5.67 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $8.00 to $2.00. This represents a potential 66.76% upside from RLMD's last price of $3.40.

RLMD Analyst Ratings


Buy

According to 2 Wall Street analysts, Relmada Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for RLMD stock is 0 'Strong Buy' (0.00%), 1 'Buy' (50.00%), 0 'Hold' (0.00%), 1 'Sell' (50.00%), and 0 'Strong Sell' (0.00%).

Relmada Therapeutics Price Target by Analyst


DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jun 05, 2024Andrea TanGoldman Sachs$2.00$2.95-32.20%-41.18%
Oct 13, 2022Andrew TsaiJefferies$8.00$6.4723.55%135.29%
Oct 13, 2022Jay OlsonOppenheimer$7.00$6.753.73%105.88%
Row per page
Go to

The latest Relmada Therapeutics stock forecast, released on Jun 05, 2024 by Andrea Tan from Goldman Sachs, set a price target of $2.00, which represents a -32.20% decrease from the stock price at the time of the forecast ($2.95), and a -41.18% decrease from RLMD last price ($3.40).

Relmada Therapeutics Price Target by Period


1M3M12M
# Anlaysts--1
Avg Price Target--$2.00
Last Closing Price$3.40$3.40$3.40
Upside/Downside-100.00%-100.00%-41.18%

In the current month, the average price target of Relmada Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Relmada Therapeutics's last price of $3.40. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades


DateCompanyPrevious RatingNew RatingRating Change
Sep 16, 2024Jefferies-BuyUpgrade
Jun 05, 2024Goldman Sachs-SellDowngrade
Oct 13, 2022Oppenheimer-PerformDowngrade
Row per page
Go to

Relmada Therapeutics's last stock rating was published by Jefferies on Sep 16, 2024. The company Upgrade its RLMD rating from "null" to "Buy".

Relmada Therapeutics Financial Forecast


Relmada Therapeutics Revenue Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
Revenue-------
Avg Forecast-------
High Forecast-------
Low Forecast-------
# Analysts-------
Surprise %-------

Relmada Therapeutics's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. RLMD's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).

Relmada Therapeutics EBITDA Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-------
EBITDA-------
Avg Forecast-------
High Forecast-------
Low Forecast-------
Surprise %-------

undefined analysts predict RLMD's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Relmada Therapeutics's previous annual EBITDA (undefined) of $NaN.

Relmada Therapeutics Net Income Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-------
Net Income-------
Avg Forecast$-30.78M$-26.86M$-22.63M$-19.01M$-18.86M$-20.37M$-24.97M
High Forecast$-30.78M$-26.86M$-22.63M$-19.01M$-18.86M$-20.05M$-24.97M
Low Forecast$-30.78M$-26.86M$-22.63M$-19.01M$-18.86M$-20.68M$-24.97M
Surprise %-------

Relmada Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. RLMD's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Relmada Therapeutics SG&A Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-------
SG&A-------
Avg Forecast-------
High Forecast-------
Low Forecast-------
Surprise %-------

Relmada Therapeutics's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to RLMD last annual SG&A of $NaN (undefined).

Relmada Therapeutics EPS Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-------
EPS-------
Avg Forecast$-1.02$-0.89$-0.75$-0.63$-0.63$-0.68$-0.83
High Forecast$-1.02$-0.89$-0.75$-0.63$-0.63$-0.66$-0.83
Low Forecast$-1.02$-0.89$-0.75$-0.63$-0.63$-0.69$-0.83
Surprise %-------

According to undefined Wall Street analysts, Relmada Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to RLMD previous annual EPS of $NaN (undefined).

Relmada Therapeutics Peer Comparison by Price Target


TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
RAPTRAPT Therapeutics$2.72$42.201451.47%Hold
PMVPPMV Pharmaceuticals$1.66$24.751390.96%Buy
IPSCCentury Therapeutics$1.39$20.001338.85%Buy
STTKShattuck Labs$1.23$12.00875.61%Hold
NUVBNuvation Bio$2.54$6.75165.75%Buy
ELYMEliem Therapeutics$5.11$13.00154.40%Buy
BCYCBicycle Therapeutics$23.64$54.40130.12%Buy
NAMSNewAmsterdam Pharma Company$21.78$36.5067.58%Buy
RLMDRelmada Therapeutics$3.40$5.6766.76%Buy
CYTKCytokinetics$55.50$83.2349.96%Buy
DYNDyne Therapeutics$29.81$43.8847.20%Buy
DICEDICE Therapeutics$47.55$60.0026.18%Buy
GRPHLENZ Therapeutics$3.18$4.0025.79%Hold
EWTXEdgewise Therapeutics$36.62$45.0022.88%Buy
THRDThird Harmonic Bio$13.27$16.1521.70%Buy
RVMDRevolution Medicines, Inc. Warrant$59.42$59.00-0.71%Buy
KRTXKaruna Therapeutics$329.83$257.50-21.93%Buy
FUSNFusion Pharmaceuticals$21.55$15.25-29.23%Hold
CYTCyteir Therapeutics$3.02$2.00-33.77%Sell

RLMD Forecast FAQ


Yes, according to 2 Wall Street analysts, Relmada Therapeutics (RLMD) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 50.00% of RLMD's total ratings.

Relmada Therapeutics (RLMD) average price target is $5.67 with a range of $2 to $8, implying a 66.76% from its last price of $3.4. The data is based on 2 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

According to Wall Street analysts' prediction for RLMD stock, the company can go up by 66.76% (from the last price of $3.4 to the average price target of $5.67), up by 135.29% based on the highest stock price target, and down by -41.18% based on the lowest stock price target.

RLMD's average twelve months analyst stock price target of $5.67 supports the claim that Relmada Therapeutics can reach $5 in the near future.

Relmada Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-64.196M (high $-63.882M, low $-64.509M), average SG&A $0 (high $0, low $0), and average EPS is $-2.127 (high $-2.117, low $-2.138). RLMD's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-99.273M (high $-99.273M, low $-99.273M), average SG&A $0 (high $0, low $0), and average EPS is $-3.29 (high $-3.29, low $-3.29).